Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Down 47.2% in June

Posted by Stanley Muller on Jul 16th, 2026

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 102,058 shares, a drop of 47.2% from the June 15th total of 193,285 shares. Approximately 2.4% of the shares of the stock are short sold. Based on an average daily volume of 212,492 shares, the short-interest ratio is presently 0.5 days.

Cyclacel Pharmaceuticals Price Performance

Shares of BGMS stock traded down $0.04 during trading hours on Thursday, hitting $0.86. 13,933 shares of the company’s stock were exchanged, compared to its average volume of 1,137,175. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $19.87. The stock has a market cap of $4.76 million, a price-to-earnings ratio of -0.19 and a beta of -0.38. The stock’s 50-day moving average is $0.93 and its 200-day moving average is $1.04.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $0.78 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Cyclacel Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Analysis on BGMS

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.